Onconova Therapeutics Inc
0.0504 (4.42%)
Upgrade to Real-Time
Regular Market
Volume 89,367
Bid Price 1.21
Ask Price 1.23
News -
Day High 1.22


52 Week Range


Day Low 1.1103
Company Name Stock Ticker Symbol Market Type
Onconova Therapeutics Inc ONTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0504 4.42% 1.1904 11:24:15
Open Price Low Price High Price Close Price Prev Close
1.15 1.1103 1.22 1.14
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
317 89,367 $ 1.17 $ 104,485 - 0.62 - 2.04
Last Trade Time Type Quantity Stock Price Currency
11:24:34 1 $ 1.23 USD


Draw Mode:

Onconova Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 24.91M 20.93M 20.83M $ 226.00k $ - -0.97 -1.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 200.00k 3.10%

more financials information »

Onconova Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.8461.490.8461.191,076,5620.344440.71%
1 Month0.731.490.69621.13338,5180.460463.07%
3 Months0.711.490.621.01175,9860.480467.66%
6 Months1.431.490.621.01118,297-0.2396-16.76%
1 Year1.842.040.621.27124,276-0.6496-35.3%
3 Years4.2019.300.628.0710,385,625-3.01-71.66%
5 Years180.00208.500.629.467,416,713-178.81-99.34%

Onconova Therapeutics Description

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.